EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of Mutation Risk Using Patient‐Derived Organoids in Patients With Lynch Syndrome

Youmi Shin, Dong Keon Kim, Yoojeong Seo, Hyeon Hee Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Jongwon Oh, Sanghoo Lee, Tae Il Kim iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Youmi Shin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine and Institute of Gastroenterology, Severance Hospital, Yonsei University College of Med…. Hauptthemen laut MEDLINE: Organoids, Colorectal Neoplasms, Hereditary Nonpolyposis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yonsei University College of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lynch syndrome (LS) is a hereditary cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes, most notably associated with colorectal cancer. Although LS patients face high risk of CRC, risk can vary even among those with the same pathogenic MMR germline mutations. We suggest a functional assay platform for assessing mutation risk using patient‐derived organoid (PDOs). We measured organoid response to the cytotoxic effects of a methylating agent, N ‐methyl‐ N′ ‐nitro‐ N ‐nitrosoguanidine (MNNG) based on DNA damage‐induced apoptosis. When normal (non‐LS) colon organoids were used, treatment with MNNG and four passages of organoid culture led to decreased total growth (organoid area), but there was no significant change in number. To increase the effect of MNNG and induce apoptosis in normal colon organoids, we added O 6 BG (an MGMT inhibitor) and an ATR inhibitor. The cytotoxic effects of combined treatment with MNNG, O 6 BG and ATR inhibitor on non‐LS‐PDOs were significantly higher than in PDOs of LS patients. To detect the difference at an earlier phase, we examined DNA damage response by analyzing γH2AX expression after treatment with MNNG and O6BG for 24 h. Then, we found higher expression of γH2AX in non‐LS‐PDOs than in PDOs of LS patients, suggesting continued cell survival with mutation accumulation in LS‐PDOs. In conclusion, treatment with MNNG and O6BG using PDOs and measurement of resulting DNA damage response could be used as a preclinical platform for risk stratification in LS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsColorectal Neoplasms, Hereditary NonpolyposisHumansApoptosisDNA DamageMethylnitronitrosoguanidineFemaleDNA Mismatch RepairGerm-Line MutationMaleMutationMiddle AgedColon

Stichwörter der Autor:innen

Lynch syndromecolorectal cancermutationorganoid

Substanzen

Methylnitronitrosoguanidine

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine and Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Yonsei Cancer Prevention Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Laboratory Medicine, Seoul Clinical Laboratories, Yongin-si, Gyeonggi-do, Korea.
  • Companion Biomarker Center, Seoul Clinical Laboratories Healthcare Inc, Yongin-si, Gyeonggi-do, Korea.

ORCID-Profile: Tae Il Kim

Förderung

  • Yonsei University College of Medicine

Zitieren

APA

Shin, Y., Kim, D. K., Seo, Y., Lee, H. H., Park, J., Park, S. J., Park, J. J., Cheon, J. H., Oh, J., Lee, S., & Kim, T. I. (2026). Evaluation of Mutation Risk Using Patient‐Derived Organoids in Patients With Lynch Syndrome. International Journal of Cancer. https://doi.org/10.1002/ijc.70646

Vancouver

Shin Y, Kim DK, Seo Y, Lee HH, Park J, Park SJ, et al. Evaluation of Mutation Risk Using Patient‐Derived Organoids in Patients With Lynch Syndrome. International Journal of Cancer. 2026. doi:10.1002/ijc.70646

BibTeX
@article{Shin2026,
  author = {Shin, Youmi and Kim, Dong Keon and Seo, Yoojeong and Lee, Hyeon Hee and Park, Jihye and Park, Soo Jung and Park, Jae Jun and Cheon, Jae Hee and Oh, Jongwon and Lee, Sanghoo and Kim, Tae Il},
  title = {Evaluation of Mutation Risk Using Patient‐Derived Organoids in Patients With Lynch Syndrome},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70646}
}
Kostenlos starten →